Company GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-16 am EST			5-day change	1st Jan Change
0.0322 ^EUR	+6.62%		+8.78%	+2.55%

25-10-15	GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report	CI
25-10-15	Geneuro SA postpones publication of half-yearly financial report	RE

Business description: GeNeuro SA

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.

Number of employees: 17

Sales by Activity: GeNeuro SA

Fiscal Period: December	2019 (EUR)	2020 (EUR)	2021 (EUR)	2022 (EUR)	2023 (EUR)

See all business segments

Geographical breakdown of sales: GeNeuro SA

Fiscal Period: December	2019 (EUR)	2020 (EUR)	2021 (EUR)	2022 (EUR)	2023 (EUR)

See all geographic segments

Executive Committee: GeNeuro SA

Manager	Title	Age	Since
Jesús Martin-Garcia CEO	Chief Executive Officer	64	2005-12-31
Hervé Perron CTO	Chief Tech/Sci/R&D Officer	68	2005-12-31
Miguel Payró DFI	Director of Finance/CFO	64	2015-10-31
Anke Post CTO	Chief Tech/Sci/R&D Officer	-	2024-01-04
Alois B. Lang PRN	Corporate Officer/Principal	75	-

See GENEURO SA governance

Composition of the Board of Directors: GeNeuro SA

Director	Title	Age	Since
Jesús Martin-Garcia CHM	Chairman	64	2006-02-05
Michel Dubois BRD	Director/Board Member	83	2008-07-15
Giacomo di Nepi BRD	Director/Board Member	74	2015-07-20
Gordon Francis BRD	Director/Board Member	77	2015-03-16
Hedi Brahim BRD	Director/Board Member	45	2020-05-26
Philippe Archinard BRD	Director/Board Member	65	2021-05-26
Sandrine Flory BRD	Director/Board Member	54	2024-03-17
Pascal Lemaire BRD	Director/Board Member	51	2024-03-17

Composition of the Board of Directors

Shareholders: GeNeuro SA

Name	Equities	%	Valuation
Eclosion2 SA 19.32 %	5,750,108	19.32 %	212 064 €
Clay Asset Management SAS 0.2887 %	85,917	0.2887 %	3 169 €

List of GENEURO SA shareholders

Company details: GeNeuro SA

GeNeuro SA (Switzerland)

3, chemin du Pré-Fleur

1228, Plan-les-Ouates

+41 22 552 48 00

http://www.geneuro.ch

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GENEURO SA	+6.62%	+8.78%	-75.23%	-97.85%	1.11M
LONZA GROUP AG	-0.89%	+1.01%	+0.87%	+12.27%	48.93B
IQVIA HOLDINGS INC.	-1.49%	-1.95%	+20.43%	+7.29%	40.48B
BEONE MEDICINES AG	-0.03%	+0.09%	+60.98%	+26.34%	37.42B
CELLTRION, INC.	-0.71%	-3.69%	+20.76%	+39.59%	31.03B
REVOLUTION MEDICINES, INC.	-2.43%	+1.38%	+198.54%	+339.30%	23.25B
MEDPACE HOLDINGS, INC.	-1.16%	+2.67%	+81.09%	+167.21%	17.21B
Average	-0.01%	+1.38%	+43.92%	+70.59%	28.33B
Weighted average by Cap.	-1.03%	-0.10%	+49.45%	+69.97%